Aytu BioPharma(AYTU) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results Net income of $0.8 million Adjusted EBITDA1 of$1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023 $20.4 million cash balance at December 31, 2024 Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time Consumer Health – Discontinued Operations DENVER, ...